Skip to main content
. 2023 Nov 2;11(11):e006702. doi: 10.1136/jitc-2023-006702

Figure 3.

Figure 3

Combination with anti-PD-L1 and dose-dependence of the antitumor efficacy of MVA.scIL-12 against aggressive PCa mouse models. (A) BALB/c mice were challenged i.p. with 2×105 CT26 colon cancer cells. Seven days later, mice were treated i.p. with 5×107 TCID50 of MVA.empty or MVA.scIL-12. C57BL/6 mice were challenged i.p. with 1×106 ID8.Vegf/GFP ovarian cancer cells. Five days later, mice were treated i.p. with 5×107 TCID50 of MVA.empty or MVA.scIL-12. Mice were treated in combination with 200 µg of the antibody anti-PD-L1 by i.p. administrations on days +1, +3, and +6 post-MVA treatment. InVivoMAb polyclonal rat IgG (Isotype) was used as a control. The Kaplan-Meier survival curves are shown. (B) As in A, vectors were administered on days 7, 10, and 13 (CT26) or on days 5, 8, and 11 (ID8.Vegf/GFP). Data are represented as mean±SEM. Log-rank test. *p<0.05; **p<0.01; ****p<0.0001. i.p., intraperitoneal; MVA, modified vaccinia virus Ankara; MVA.scIL-12, MVA encoding scIL-12; PCa, peritoneal carcinomatosis; PD-L1, programmed death-ligand 1; scIL-12, single-chain interleukin 12; TCID50, 50% tissue culture infectious dose.